Source: Sharecast

Affinivax: GlaxoSmithKline to buy US biotech Affinivax in $3.3bn deal

Drugmaker GlaxoSmithKline said on Tuesday that it had agreed to acquire Boston-based clinical-stage biopharmaceutical company Affinivax as part of a deal valued at as much as $3.3bn.

Read full article »

Affinivax's Competitors | Affinivax's News | Affinivax's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

25-100

President & CEO

Steven Brugger

CEO Approval Rating

86/100

Affinivax is a Massachusetts-based biopharmaceutical company that develops and commercializes novel vaccines for the treatment of infectious diseases.